INZY
- Inozyme Pharma, Inc.
()
Overview
Company Summary
Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of novel treatments for rare diseases that are caused by abnormal mineralization. The company's primary goal is to address rare genetic disorders known as calcified conditions, where abnormal buildup of minerals occurs in various organs and tissues throughout the body.
Inozyme Pharma is specifically focused on developing enzyme replacement therapies (ERT) and enzyme enhancement therapies (EET) to target the underlying causes of these calcified conditions. ERTs involve introducing exogenous enzymes into the body to replace the deficient or malfunctioning enzymes, while EETs work to enhance the activity of existing enzymes to restore their normal function.
These therapies aim to correct the misregulation of mineral metabolism and reduce the abnormal mineralization in affected tissues and organs. Inozyme Pharma's research and development efforts focus on advancing the understanding of the biology behind calcified conditions and discovering innovative treatments to address the unmet medical needs in this field.
By developing targeted therapies, Inozyme Pharma strives to improve the quality of life for patients suffering from rare genetic disorders associated with abnormal mineralization. The company collaborates with research institutions, physicians, and patient advocacy groups to ensure the development of effective and safe treatments while maintaining a patient-centric approach.